Historically, the company has been releasing figures that are above expectations.
The stock, which is currently worth 2020 to 0.7 times its sales, is clearly overvalued in comparison with peers.
This company will be of major interest to investors in search of a high dividend stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
Technically, the stock approaches a strong medium-term resistance at USD 74.14.
According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company has insufficient levels of profitability.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
For the past year, analysts have significantly revised downwards their profit estimates.